Key Highlights
- In intraday data on Thursday, November 19, 2026, SELLAS Life Sciences (NASDAQ:SLS) stood 13.98% lower at USD 15.44, two days after it launched an underwritten common stock offering.
- The base offering is USD 150.0 million, announced November 17, 2026. Underwriters can take a 30-day option on up to USD 22.5 million more, and every share is sold by the company.
- J.P. Morgan and TD Cowen act as joint book-running managers, using a Form S-3 shelf registration filed March 20, 2026 that became effective automatically upon filing.
- At September 30, 2026 the company held USD 134.7 million of cash, with 203,527,833 shares outstanding before any new shares or underwriter option are counted.
A Phase 3 Rally Followed by a Fresh Equity Raise
Shares of SELLAS Life Sciences (NASDAQ:SLS) changed hands at USD 15.44 on November 19, 2026, a 13.98% decline in intraday data, suggesting the earlier close was near USD 17.95 (a calculated figure). The slide followed a November 17, 2026 release describing how the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia reached its overall survival target. Median survival reached 24.0 months, versus 14.7 months for the best available treatment, with a 0.59 hazard ratio and a 0.035 p-value. The offering launched later that same day. No price per share appeared in the release, and no final pricing turned up in searches for this article, leaving the discount to market unknown.
Why New Shares Can Press Down a Stock Price
SELLAS is a late-stage biopharmaceutical developer of cancer treatments. Its lead candidate, galinpepimut-S, targets the WT1 protein and was licensed from Memorial Sloan Kettering Cancer Center, while SLS009 (tambiciclib), a CDK9 inhibitor, is aimed at leukemia patients with unfavourable prognostic factors. Because the company is the only seller, the deal adds shares and spreads ownership across a larger base. Underwriters commonly set prices below the last trade to place the whole block, which can weigh on the stock that day. The USD 150.0 million figure works out to roughly 4% of an equity value of about USD 3.1 billion, a calculation based on 203.5 million shares at USD 15.44 that leaves out new shares. The release gave no detail on how proceeds will be used.
Cash Position, Regulatory Timeline and Execution Risk
Cash stood at USD 134.7 million, and the third-quarter net loss was USD 10.1 million, both reported on November 12, 2026. Management intends to talk with the FDA about an accelerated filing approach and aims to file a Biologics License Application during the first half of 2027. New Capital would support that effort, yet risks remain: the REGAL study was open-label, its p-value sits only modestly under 0.05, the sample included 126 patients, and regulators could ask for further data. Whether the deal closes on set terms depends on market conditions, so timing, size and pricing remain open. Thin trading means a few orders can shift the quote, and such moves can reverse.
Where Things Stand
Probably the offering, though this remains an inference. The 13.98% decline lines up with a freshly launched equity raise that followed a sharp rally on Phase 3 data, and the trial results themselves have not changed. SELLAS Life Sciences (NASDAQ:SLS) is issuing new shares, the final price is still unconfirmed, and holders must weigh dilution against the capital it brings to the REGAL filing path. Watch for the offering's final pricing, an FDA meeting on an accelerated filing path, secondary REGAL analyses, a medical conference presentation and the application planned for the opening half of 2027.




_11_19_2026_18_29_00_678569.jpg)

Please wait processing your request...